FV-100: the most potent and selective anti-varicella zoster virus agent reported to date.
Bicyclic aryl furano pyrimidines represent the most potent anti-varicella zoster virus (VZV) agents reported to date. Lead compounds have 50% effective concentration (EC(50)) values in vitro that are in the subnanomolar range and selectivity index values that exceed 1 million. They have an absolute requirement for VZV thymidine kinase and most likely act as their phosphate forms. Some structural modification (such as aryl substitution in the base moiety) is tolerated, whereas little sugar modification is acceptable. The Cf1743 compound has proved to be significantly more potent than all reference anti-VZV compounds, as measured either by inhibition of infectious virus particles and/or viral DNA production; however, the high lipophilicity and very low water solubility of this compound gives poor oral bioavailability (<14%). Use of the modified cyclodextrin captisol and the synthesis of the 5'-monophosphate prodrug of Cf1743 has significantly improved water solubility, but does not give any enhancement in oral bioavailability. By contrast, the synthesis of the ether series does not give any further improvement in terms of solubility. The most promising prodrug to emerge to date is the hydrochloric salt of the 5'-valyl-ester, designated as FV-100. Its uptake into cells has been studied using fluorescent microscopy and biological assays, which have indicated that the compound is efficiently taken up by the cells after a short period of incubation.
Migliore
Marco
M
School of Chemistry, University of Leeds, Leeds, UK. m.migliore@leeds.ac.uk
D000998:Antiviral Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006562:Herpes Zoster / Q000188:drug therapy*; D014645:Herpesvirus 3, Human / Q000254:growth & development*; D006801:Humans; D011741:Pyrimidine Nucleosides / Q000494:pharmacology* / Q000627:therapeutic use
D000998:Antiviral Agents; C526677:FV-100; D011741:Pyrimidine Nucleosides